Migraine And Headache

Migraine Patch Product No Longer Available

By October 20, 2017

Zecuity, launched in September 2015, is a transdermal system that delivers a therapeutic dose via a single-use, battery-powered patch wrapped around the upper arm or thigh.

Non-Opioid Tx Beats Hydromorphone for Migraine Pain Relief in the ED

By October 19, 2017

Participants were randomized to either hydromorphone 1mg (n=64) or prochlorperazine 10mg plus diphenhydramine 25mg (n=62).

BLA Submitted for Migraine Prevention Drug Fremanezumab

By October 17, 2017

The studies looked at the safety, tolerability, and efficacy of 4 dose regimens of subcutaneous fremanezumab vs. placebo over 16 weeks.

New Type of Chronic Daily Headache Described in Case Series

By September 26, 2017

With regards to treatment, all of the patients responded to CSF pressure-/volume-lowering therapies (ie, acetazolamide or spironolactone).

FDA Clears Cefaly Device for Use During Migraine Attack

By September 21, 2017

Cefaly Acute is an external trigeminal nerve stimulator (e-TNS) approved for use under prescription.

Investigational Migraine Tx Shows Promise in Phase 3 Trial

By September 14, 2017

Results demonstrated that at 12 weeks after the first dose of fremanezumab, the CM group had reductions of monthly headaches; -4.6 days for the monthly dose, -4.3 days for the quarterly dose and -2.5 for the placebo group (P<0.0001).

Oxygen Tx for Cluster Headache 'Not Prohibitively Expensive', Study Says

By September 14, 2017

The study concluded that the cost of medical grade oxygen for the acute treatment of CH is not prohibitively expensive for patients or for insurance providers.

Does Alcohol Consumption Increase the Risk of Migraine Attack?

By September 11, 2017

Of the total migraine sufferers, alcohol was deemed a risk factor for 64% of them.

Cardiovascular Study Supports Safety of Novel Migraine Tx Erenumab

By September 11, 2017

Results showed that at the end of the 12-week trial participants in the Aimovig 140mg group had a reduction of 7 MMDs and the 70mg group had a reduction of 5.4 days, while the placebo group had a reduction of 2.7 days (P<0.001).

Device for Migraine Prevention and Treatment Gets FDA Clearance

By September 07, 2017

The non-invasive SpringTMS device is placed at the back of the patient's head where a forced magnetic pulse is delivered to treat an acute attack or to prevent a future migraine onset.

Migraine Drug Therapies Examined for Appropriateness

August 28, 2017

The study team found that of 2,860 Americans who visited the doctor for migraine relief, 15.2% were prescribed opioids.

Opioids Greatly Overused as Migraine Treatment, Study Finds

By August 17, 2017

For abortive medications, results showed that overall 18.9% of patients received all high quality abortive medication, 27% received some low quality abortive while 15.2% received opioids.

Investigational Migraine Drug Lasmiditan Effective in Phase 3 Study

By August 04, 2017

Results showed that a statistically significant number of those participants who received lasmiditan (in all doses) were pain-free at 2-hours post dosage compared to those who received placebo (the primary endpoint).

FDA Clears Non-Invasive Device to Treat Chronic Intractable Pain

By August 03, 2017

The Stimpod NMS460 includes a nerve-mapping pen-like probe which allows practitioners to locate nerves and evaluate the treatment progress.

CAM Use Among Migraine/Headache Sufferers Investigated

By August 02, 2017

The use of complementary and alternative medicine (CAM) specifically for the treatment of migraine and headache is "relatively low" in the U.S.

Teva Launches Generic Relpax

By August 02, 2017

Its agonist effects at the 5-HT1B/1D receptors on intracranial blood vessels and sensory nerves of the trigeminal system result in cranial vessel constriction and inhibition of pro-inflammatory neuropeptide release.

Aimovig for Migraine Prophylaxis Under FDA Review

By July 21, 2017

If approved by the FDA, Aimovig will be the first monoclonal antibody targeting the calcitonin gene-related peptide (CGRP) receptor specifically intended for migraine prophylaxis.

Drug-Free Cluster Headache Therapy Now Available

By July 18, 2017

The Food and Drug Administration (FDA) approved gammaCore in April after efficacy was demonstrated in two clinical trials involving over 200 patients with episodic cluster headaches (ACT1 and ACT2).

Is Telemedicine Viable for Long-Term Treatment of Headaches?

June 15, 2017

The study findings suggest that telemedicine may be valuable for headache sufferers who want to see a specialist without extra hassle or inconvenience, he said.

Non-Invasive Device Effective in Patients with Refractory Migraine

By June 12, 2017

Results showed that after three months, the use of Cefaly was associated with a statistically significant, albeit small, reduction in the number of headache days.

Galcanezumab Shown to Significantly Cut Monthly Migraine Days

By June 10, 2017

Patients in the galcanezumab group had statistically significant greater reduction in monthly migraine headache days with acute medication use compared to placebo.

A View to a Headache: Health Implications of Modern Urban Design

June 09, 2017

People who get migraines are particularly susceptible to the discomfort from repetitive patterns.

CGRP Targeted Drug Looks Promising for Migraine Prevention

By May 31, 2017

The HALO Clinical Research Program consists of two 16-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group studies that compared fremanezumab to placebo in adults with episodic and chronic migraine.

Biologic for Migraine Prevention Submitted to FDA

By May 18, 2017

Amgen announced the submission of a Biologics License Application (BLA) to the Food and Drug Administration (FDA) for erenumab for the prevention of migraines.

Riboflavin May Be Effective for Some Migraine Sufferers

By May 16, 2017

The authors concluded that for adult prophylaxis, riboflavin "is well tolerated, inexpensive and most controlled clinical trials have shown modest reductions in migraine headache frequency."

Once-Monthly Biologic Looks Promising for Migraine Prophylaxis

By May 12, 2017

Lilly announced encouraging results from three Phase 3 studies of galcanezumab, EVOLVE-1, EVOLVE-2 and REGAIN, evaluating its efficacy and safety for the prevention of episodic and chronic migraine.

Erenumab for Chronic Migraine Prevention

By April 28, 2017

Tepper, Stewart et al. "Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomized, double-blind, placebo-controlled phase 2 trial". DOI: 10.1016/S1474-4422(17)30083-2.

Promising Results for Novel IV Migraine Therapy

By April 28, 2017

Results met the primary endpoint of a significant reduction in migraine days for the eptinezumab groups, as measured by 75% responder rates.

Novel, Non-Drug Therapy Gets FDA OK for Cluster Headaches

By April 18, 2017

The device is applied to the neck and transmits a mild electrical stimulation to the vagus nerve through the skin.

Weight and Migraine Occurrence: Is There a Link?

April 13, 2017

Obese people 27% more likely to have migraines; underweight 13% more likely.